Bloomberg
Dr. Reddy’s Sees Weight-Loss Drug Boosting Growth After Setback
Thursday, July 30, 2026
Dr. Reddy's Laboratories Ltd. identified an impurity issue in its generic anti-obesity drug and halted supply. The company expects to resume supply in early November. Dr. Reddy's anticipates the drug will support growth in the six months through March 2026.